|  | 1st line | 2nd line (n = 41) | 3rd line (n = 20) | ||
---|---|---|---|---|---|---|
IFN-alpha | IFN-alpha + sorafenib | Axitinib | ||||
CR/PR/SD > 24w (n = 6) | CR/PR/SD > 24w (n = 19) | SD < 24w/PD (n = 22) | CR/PR/SD > 24w (n = 9) | SD < 24w/PD (n = 11) | ||
Sex (Male / Female) | 32 / 15 | Â | Â | Â | Â | Â |
Years (median) | 39–78 (65) |  |  |  |  |  |
ECOG PSa (0 / 1 / 2) | 29 / 14 / 4 | 6 / 0 / 0 | 13 / 6 / 0 | 10 / 8 / 4 | 4 / 5 / 0 | 2 / 8 / 1 |
MSKCCa (Fav / Int / Poor) | 24 / 15 / 8 | 6 / 0 / 0 | 9 / 7 / 0 | 9 / 8 / 8 | 2 / 7 / 0 | 1 / 8 / 2 |
Duration of IFN-alphaa (mean: months) |  | 7–46 (15.9) |  |  |  | |
Duration of pre-IFN-alphaa (mean: months) |  |  | 1–31 (7.4) |  |  | |
Duration of IFN-alpha + sorafenib (mean: months) |  |  | 1–81 (19.7) |  |  | |
Duration of axitinib (mean: months) |  |  |  |  | 1–37 (11.6) | |
Metastatic lesionsa (numbers) | ||||||
 PUL | 46 | 6 | 18 | 22 | 9 | 11 |
 PLE | 6 | 1 | 2 | 3 | 2 | 2 |
 HEP | 7 | 0 | 3 | 4 | 2 | 2 |
 OSSa | 11 | 0 | 6 | 5 | 3 | 3 |
 LYM | 12 | 0 | 6 | 6 | 3 | 4 |
 Others | 3 | 0 | 0 | 3 | 0 | 2 |